Earnings ·
Reports Q3 revenue of $361.0M and raises full-year guidance to $1.36-$1.37B
GHGuardant Health, Inc.
Guardant Health reported third-quarter 2026 total revenue of $361.0 million, a 36% increase from the prior year period, driven by strong growth in Oncology (up 25%) and Screening (up 180%). The company raised its full-year 2026 revenue guidance to $1.36 billion–$1.37 billion, representing 38%–40% growth compared to the previous outlook of $1.34 billion–$1.36 billion. Non-GAAP net loss narrowed to $38.8 million from $48.3 million in the year-ago quarter. Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.